Revance Therapeutics, Inc.

D. E. Shaw & Co., Inc.

Report date

12/31/2024

Quarter

2024 Q4

Filed

2/14/2025

Shares

1,367,343

Value ($000)

4,157

Weight

0.0%

2020 Q1 - 2024 Q4 (18 filings)

Shares History

History scope: non-option holdings only (PUT/CALL rows excluded).

All 13F Holders	Filing date	Value ($000s)	% of Holdings	Shares	Reporting period
2024 Q4	2/14/2025	4,157	0.0%	1,367,343	12/31/2024
2024 Q3	11/14/2024	10,028	0.0%	1,932,205	9/30/2024
2024 Q2	8/14/2024	278	0.0%	107,980	6/30/2024
2023 Q4	2/14/2024	3,619	0.0%	411,750	12/31/2023
2023 Q3	11/14/2023	8,970	0.0%	782,016	9/30/2023
2023 Q2	8/14/2023	50,915	0.1%	2,011,669	6/30/2023
2023 Q1	5/15/2023	73,822	0.1%	2,291,911	3/31/2023
2022 Q4	2/14/2023	24,716	0.0%	1,338,920	12/31/2022
2022 Q3	11/14/2022	39,678	0.1%	1,469,573	9/30/2022
2022 Q2	8/15/2022	11,302	0.0%	817,740	6/30/2022
2022 Q1	5/16/2022	16,502	0.0%	846,268	3/31/2022
2021 Q4	2/14/2022	8,550	0.0%	523,918	12/31/2021
2021 Q3	11/15/2021	257	0.0%	9,240	9/30/2021
2021 Q2	8/16/2021	1,425	0.0%	48,087	6/30/2021
2020 Q4	2/16/2021	253	0.0%	8,933	12/31/2020
2020 Q3	11/16/2020	794	0.0%	31,584	9/30/2020
2020 Q2	8/14/2020	271	0.0%	11,111	6/30/2020
2020 Q1	5/15/2020	182	0.0%	12,300	3/31/2020